Nowak ADepartment of Endocrinology and Clinical Nutrition, University Hospital Zurich, Switzerland / Department of Internal Medicine, Psychiatry University Hospital Zurich, Switzerland.
Angelillo-Scherrer ADepartment of Haematology and Central Haematology Laboratory, Bern University Hospital, Inselspital, University of Bern, Switzerland.
Betticher DClinics of Medical Oncology, HFR Fribourg Cantonal Hospital, Switzerland.
Dickenmann MClinic for Transplantation Immunology and Nephrology, University Hospital Basel, Switzerland.
Guessous IDivision of Primary Care Medicine, Department of Primary Care Medicine, Geneva University Hospitals, Switzerland.
Juillerat PDepartment of Gastroenterology, Clinic for Visceral Surgery and Medicine, Bern University Hospital, Switzerland.
Korte WCentre for Laboratory Medicine, and Haemostasis and Haemophilia Centre, St Gallen, Switzerland.
Neuner-Jehle SInstitute of Primary Care, University and University Hospital Zurich, Switzerland.
Pfister ODivision of Cardiology, University Hospital Basel, Switzerland.
Surbek DDepartment of Obstetrics and Gynaecology, Bern University Hospital, University of Bern, Switzerland.
Battegay EDepartment and Outpatient Clinic for Internal Medicine, University Hospital Zurich, Switzerland.
Steurer JHorten Centre for Patient Oriented Research and Knowledge Transfer, University Hospital Zurich, Switzerland.
English
AIMS OF THE STUDY Iron deficiency (ID) and iron deficiency anaemia (IDA) are important conditions affecting a large proportion of the general population, causing the patients physical and psychosomatic symptoms, particularly fatigue, and significantly affecting their quality of life. General practitioners (GPs) are frequently consulted with nonspecific symptoms due to the ID. However, little evidence is available to guide iron treatment. The aim of the Swiss Delphi study was to generate a broad consensual Swiss expert opinion in various therapeutic areas on diagnosis and treatment of ID/IDA and their practical implications.
METHODS Specific statements regarding clinical relevance, practical diagnostic and therapeutic approaches, and treatment were evaluated by Swiss experts in various therapeutic areas using the Delphi method. “Consensus” was defined as ≥80% agreement; the agreement of 50–79% was defined as “critical”, of <50% as “disagreement”.
RESULTS Consensus was reached for most statements. In patients without systemic inflammation, the threshold of 30 μg/l provide a good accuracy for the diagnosis of ID without anaemia. Ferritin levels within the range 30–50 μg/l with TSAT <20% can indicate ID without anaemia. Iron replacement therapy is accepted for treatment, not only of IDA, but also of symptomatic ID without anaemia. GPs play a central role in diagnosis and management of ID.
CONCLUSIONS This consensus study provides potential therapeutic strategies for management of iron deficiency and is based on opinions of a high number of contributing specialists, providing their views from a wide range of clinical perspectives.  .